Compare EUDA & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | EUDA | GRML |
|---|---|---|
| Founded | 2021 | N/A |
| Country | Singapore | United States |
| Employees | 123 | 5 |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0M | 34.9M |
| IPO Year | N/A | 2022 |
| Metric | EUDA | GRML |
|---|---|---|
| Price | $21.00 | $0.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $55.00 | N/A |
| AVG Volume (30 Days) | 3.2K | ★ 7.7M |
| Earning Date | 12-19-2023 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $134.73 | N/A |
| Revenue Next Year | $195.03 | N/A |
| P/E Ratio | $123.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.16 |
| 52 Week High | $25.70 | $0.55 |
| Indicator | EUDA | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 69.01 | 40.28 |
| Support Level | $1.38 | $0.16 |
| Resistance Level | $25.70 | $0.34 |
| Average True Range (ATR) | 1.04 | 0.04 |
| MACD | 0.92 | 0.00 |
| Stochastic Oscillator | 90.61 | 20.04 |
EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.